Comparison of efficacy and safety of oral vs subcutaneous methotrexate in psoriasis
- Conditions
- Health Condition 1: null- Psoriasis Vulgaris
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1)Patients aged more than 18 years with clinical diagnosis of plaque psoriasis
2)Patients with body surface area involvement > 10 %, PASI >10,
1)Hemoglobin < 8 gm/dl ,Total leukocyte count < 3500/ mm3, Platelet count < 100,000/mm3
2)Elevation of hepatic enzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST], or γ glutamyl transferase [GGT]) to more than twice the upper limit of normal.
3)Hepatitis, active or recurrent, cirrhosis or excessive current alcohol intake .
4)Use of other hepatotoxic drugs by the patient
5)Positive hepatitis B, hepatitis C or HIV serology
6)Pulmonary or extra-pulmonary active tuberculosis
7)Deranged renal function test.
8)Pregnancy or lactation or if patient is planning to conceive during the treatment period.
9)Patient on other immunosuppressive drugs
10)Recent live vaccination
11)Unreliable patient
12)Patients unwilling for monthly follow-ups.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Difference in the percentage of patients who achieved PASI 90 (90 % reduction in psoriasis area severity score (PASI) compared to baseline) in both the groupsTimepoint: 0 Weeks and 12 Weeks
- Secondary Outcome Measures
Name Time Method 1.Improvement in DLQI (dermatology life quality index). <br/ ><br>2.Relapse free period after stopping treatment. <br/ ><br>3.Adverse events if any. <br/ ><br>Timepoint: baseline and 12 weeks <br/ ><br>Follow up after treatment 6 months